The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.
Ingrid A. Mayer, MD, MSCI
Advertisement
Articles by Ingrid A. Mayer, MD, MSCI
Advertisement
Latest Updated Articles
Development of PI3K Inhibitors in Breast CancerNovember 7th 2014
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
4
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
5